NHS Economic Evaluation Database
Accesskeys
- [Alt + 0] - Homepage
- [Alt + 1] - to the top
- [Alt + 5] - Search Form
- [Alt + 6] - Sitemap
- [Alt + 7] - to within-page navigation
- [Alt + 8] - to content
- [Alt + 9] - Contact Form
Global Servicelinks
Navigation
content
Detailed Information: NHS Economic Evaluation Database
(NHSEED)
NHSEED; Economic Evaluations
The NHS Economic Evaluation Database (NHSEED; Economic Evaluations) database contains bibliographical information and appraisals of economic evaluations in which costs as well as outcomes of treatment and care alternatives in health care are compared. The source of NHSEED are databases like MEDLINE and EMBASE as well as magazines (hand search) and working papers of specialised working groups, and HTA institutions. Depending on the document type a critical appraisal on the quality of the original study is offered as structured abstract. It gives information on up to forty different aspects like health technology, disease, study population, study design, type of intervention, and currency. The appraisals are written by experts of the NHS. The following study types are gathered: economic studies, cost-benefit analyses, cost-utility analyses, cost-effectiveness analyses, cost-minimisation analyses, cost-consequence analyses as well as systematic reviews of economic studies.
Content navigation
- Database Content: Subject Coverage | Type | Language | Sources | Superbases
- Database Resources: File Size | File Data | Update Cycle
- Query: Special Notes | Vocabulary | Searchable Data Fields | Data Fields, alphabetical | Output of Search Results | Sample Search(es) | Sample Record(s)
- Contact: Producer | Contact Person
- Appendix: Appendix
Database Content
| Subject Coverage | medicine, health economics |
|---|---|
| Type | Literature database |
| Language | English |
| Sources |
|
| Superbases | There are predefined databases groups (superbase) for several subjects. The database NHS Economic Evaluation Database is part of the following superbases: |
Database Resources
| File Size | 11,886 (Status 06/2012) |
|---|---|
| File Data |
You will find the number of database records in the current update status. |
| Update Cycle | Quarterly |
Query
Special Notes
The documents contain evaluations as regard content of other (referenced) articles. The field SO represents the source of the evaluation, as the field RSO indicates the source of the original article. The fields TI and AU contain the title and the author of the evaluation. The fields RTI and RA present the title and the author of the original article. The Title of the original article are showed additional in TI.
With every update the whole file is reloaded. Therefore standing orders (SDI) are not possible.
Vocabulary
Controlled Terms (CT): descriptors from the MeSH (Medical
Subject Headings), thesaurus with polyhierarchical structure.
Language of vocabulary: English
The following additional information for controlled terms (CT) is available:
| Code | Field name | Description |
|---|---|---|
| ANN | Annotations | Indexing annotations |
| AQ | Allowed Qualifier | Qualifiers allowed for limiting the controlled terms |
| CC | Classification Code | One descriptor may have several classification codes corresponding to the different branches in the polyhierarchic thesaurus |
| CR | CAS-Registry-Number | |
| DA | Date | Date, the record was added to the system |
| ECOM | Entry Combination | Information on use of combinations for related concepts |
| HIS | History-Notes | Information on entry date of the descriptor and formerly used controlled terms |
| MAE | Major Established | Introduction date as major descriptor |
| MAS | MeSH Associated Term | Drugs with the corresponding pharmacological action (PACT) |
| N1 | Preferred Name | Preferred name of chemicals |
| OLN | Online Note | Indicator to indexing |
| PACT | Pharmacological Action | Pharmacological action descriptor |
| PI | Previous Indexing | Previous Indexing |
| PMN | Public Mesh Note | Information on entry date of the descriptor and formerly used controlled terms |
| SCN | Scope Notes | Definitions |
| SYN | Synonym | Information on entry terms |
| USE | Use | Reference from entry term to main heading. |
Searchable Data Fields
The following document sections are considered with the free text search (FT):
Abstract (AB) and all included fields (see Data fields)
Corporate Author (CA)
Controlled Terms (CT)
Document Type (DT)
Publisher (PU)
Title (TI), incl. Language of Publication (PLA)
Search language(s) in the basic index: English
Data Fields, alphabetical
Explanation:
D = DISPLAY F = FIND S = SHOW
1 : front-end-masking recommended
2 : searchable word by word with field label
3 : searchable only selectively
(F): field is searchable only via basic index
| Command | Field Name | Examples | Notes |
|---|---|---|---|
| (F) S | AB Abstract | F heart/AB | The abstract field consists of a summary of different fields: AC, AEFF, CDIR, CIDIR, CLC, CRD, CRES, CRI, CSTAT, CUR, DDR, DIS, ECST, EFFR, ESEC, ESEF, HT, HYSQ, IMPS, INVS, LBEC, MCOM, MEFF, MJUD, MOB, MOD, NRPS, OTHER, OUT, RES, SENS, SETT, SRCE, SRCF, SRCS, STUD, STUI, STUP, STUS, SYOC, TOI. |
| (F) S | AC Author’s Conclusion | F postmenopausal/AC | Is part of AB. |
| (F) S | AEFF Analysis of Effectiveness | F clinic? significant/AEFF | Is part of AB. |
| D F | AI Abstract Indicator | F... AND AI=? D AI=? F AI=abstract online |
Searches for documents with an online abstract. |
| D F S | AU Author | F AU=muennig p | The field AU is equivalent to the field RA. |
| D 2 F 2 S | CA Corporate Author | F CA=dissemination | |
| D F | CC Controlled Term Code | F CC=c17.800.174 F CC D c17.800 D CC T c17.800.174 D CC=c17.800.174;ALL |
MeSH-Code Version. Requesting upper and lower level classification codes and additional information same as with CT. |
| F | /QF=xx | F CC=c17.800/QF=di F CC=c17.800/QF=(di;th) F CC D c17.800/QF=di |
Qualifying of classification codes, same as with CT. |
| (F) S | CDIR Direct Costs | F medication/CDIR | Is part of AB. |
| (F) S | CEDEEClinical and Epidemiological Data used in the Economic Evaluation | F clinical trials/CEDEE | Is part of AB. |
| (F) S | CIDIR Indirect Costs | F productivity/CIDIR | Is part of AB. |
| (F) S | CLC Clinical Conclusions | F enoxaparin/CLC | Is part of AB. |
| S | CNOTE Copyright Notice | CNOTE: Copyright: University of York, 1999. | |
| (F) S | CRD CRD Commentary | F osteoporosis/CRD | Is part of AB. |
| (F) S | CRES Cost Results | F etidronate/CRES | Is part of AB. |
| (F) S | CRI Criteria | F investigators/CRI | Is part of AB. Criteria used to ensure the validity of primary studies. |
| D 2 F 2 S | CS Corporate Source | F CS=boston | Contains the address. |
| (F) S | CSTAT Statistics of Costs | F bootstrap/CSTAT | Is part of AB. Statistical analysis of costs. |
| (F) S | CSUM CRD Summary | F cost-effectiveness/CSUM | Is part of AB. |
| D F S | CT Controlled Terms | F CT=skin diseases F infertility, male/CT D CT=skin diseases;ALL |
MeSH Requesting vocabulary. |
| F CT D skin diseases | Indented descriptors are included. | ||
| D CT T dermatitis | Requesting tree structure. | ||
| D F S | DOI Digital Object Identifier | D DOI=? F DOI="10.1002/14651858" |
Must be set in quotation marks. A DOI is a unique and persistent identification code for digital objects. |
| F | /QF = xx | F CT=skin diseases/QF=di | Search for Controlled Terms together with a Qualifier. |
| F CT=skin diseases /QF=(di;th) | Combination with several qualifiers. | ||
| (F) S | CUR Currency | F us dollars/CUR | Is part of AB. |
| D F S | CY Country of Publication | F CY=canada | Contains the country, but not the Country-Code. |
| (F) S | DATCOL Data sources | F hypothetical/DATCOL | Is part of AB. |
| (F) S | DDRRelating Data | F hypothetical/ DDR | Is part of AB. Dates to which data relate. |
| (F) S | DIS Disease | F muscul?/DIS | Is part of AB. |
| D F S | DT Document Type | F DT=abstract F abstract/DT D DT=? |
Only two document types: Abstract and Biblio. |
| (F) S | ECST Economic Study Type | F effectiveness/ECST | Is part of AB. |
| (F) S | EFFR Effectiveness Results | F composite/EFFR | Is part of AB. |
| (F) S | ESEC Estimated Benefits | F alendronate/ESEC | Is part of AB. Estimated benefits used in the economic analysis. |
| (F) S | ESEF Assumptions | F nonresectable/ESEF | Is part of AB. Estimates of effectiveness and key assumptions. |
| (F) S | HT Health Technology | F rheuma?/HT | Is part of AB. |
| (F) S | HYSQ Hypothesis/Study Question | F social?/HYSQ | Is part of AB. |
| (F) S | IMPS Implications | F guidelines/IMPS | Is part of AB. Implications of the study. |
| (F) S | INT Interventions | F programme/IMPS | Is part of AB. |
| (F) S | INVS Investigation Primary Studies | F enoxaparin/INVS | Is part of AB. Investigation of differences between primary studies. |
| D F S | ISSN International Standard Serial Number | F ISSN=1465-1858 | |
| D F S | JT Journal Title | F JT=lancet | Is part of RSO. |
| D F S | LA Language | F LA=eng | Only English language documents available. |
| (F) S | LBEC Link Effectiveness Costs | F transfusion/LBEC | Is part of AB. Link between effectiveness and cost data. |
| (F) S | LOSE Location/settingink | F hospital/LOSE | Is part of AB. |
| (F) S | MAUC Methods used to allow for Uncertainty | F Probabilistic sensitivity analysis/MAUC | Is part of AB. |
| (F) S | MCOM Methods Primary Studies | F combine/MCOM | Is part of AB. Method of combination of primary studies. |
| (F) S | MEFF Methods Estimates | F assumptions/MEFF | Is part of AB. Methods used to derive estimates of effectiveness. |
| (F) S | MJUD Methods data extracting | F heparin/MJUD | Is part of AB. Methods used to judge relevance and validity, and for extracting data. |
| (F) S | MOB Measure of Benefits | F fractures/MOB | Is part of AB. Measure of benefits used in the economic analysis. |
| (F) S | MOD Modelling | F logistic regression/MOD | Is part of AB. |
| (F) S | MODA Methods used to obtain Data | F randomised clinical trial/MODA | Is part of AB. |
| (F) S | MSE Modelling and Statistical Extrapolation | F Monte Carlo simulation#/MSE | Is part of AB. |
| D F S | ND Number of Document | F ND=NHSEED-21992000001 | |
| (F) S | NRPS Number of Primary Studies | F eighteen/NRPS | Is part of AB. Number of primary studies included. |
| (F) S | OISS Other Issues | F sample size/OISS | Is part of AB. |
| (F) S | OTHER Other Publications | F american acadamy/OTHER | Is part of AB. Other publications of related interest. |
| (F) S | OUT Outcomes | F complication rates/OUT | Is part of AB. Outcomes assessed in the review. |
| D (F) | PLA Language of Publication | F PLA=german | Is part of the TI if the language of the publication is not English. |
| (F) S | PROC Productivity Costs | F indirect costs/PROC | Is part of AB. |
| D 2 F 2 S | PU Publisher | F PU=wiley F chichester/PU |
|
| D F S | PY Publication Year | F ... AND PY>=1999 | Is part of RSO. |
| D F | QF Qualifier | F QF=classification F QF=cl |
List of qualifiers see appendix. |
| D F S | RA Referenced Author | F RA=ness rm | The field RA is equivalent to the field AU. |
| (F) S | RES Results | F nursing/RES | Is part of AB. Results of the review. |
| S | RPG Referenced Page | PAGE: p. 27-33. | Is part of RSO. |
| S | RSO Referenced Source | RSO: Cancer; VOL: 101 (11); p. 2533-2539 / 2004/ | Is the source of the original article. Consisting of journal title (JT), RVOL, RPG and PY. |
| (F) S | RTI Referenced Title | F rehabilitation/RTI | The field RTI is equivalent to the field TI. Is part of SO. |
| S | RVOL Referenced Volume |
VOL: 25(4) | Is part of RSO. |
| (F) S | SENS Sensitivity Analysis |
F medical care/SENS | Is part of AB. |
| (F) S | SETT Setting | F usa/SETT | Is part of AB. |
| S | SO Source | SO: NHS Economic Evaluation Database (NHSEED). Other economic studies: bibliographic details. Abstract of: The costs of hipfracture in Germany: a prospective evaluation (German). | Is the source of the evaluation. Contains a special format, which shows, how the reports are to be quoted. Consisting TI (incl. PLA). |
| (F) S | SRCE Source of Effectiveness |
F completed studies/SRCE | Is part of AB. Source of effectiveness data |
| (F) S | SRCF Source of Funding | F canada/SRCF | Is part of AB. |
| (F) S | SRCS Sources Searched | F medline/SRCS | Is part of AB. Sources searched to identify primary studies. |
| (F) S | STA Status | F economist/STA | Advice in the documents with DT=Abstract, if there is an
abstract to the original study (reference literature) or by whom
the abstract is written. In documents with DT=Biblio in short a reason is given why there is no abstract. |
| (F) S | STUD Study Design | F case series/STUD | Is part of AB. |
| (F) S | STUI Inclusion Criteria | F designs/STUD | Is part of AB. Study designs and other criteria for inclusion in the review. |
| (F) S | STUO Study Objectives | F haemofiltration/STUO | Is part of AB. |
| (F) S | STUP Study population | F wom#n/STUP | Is part of AB. |
| (F) S | STUS Study sample | F abnormalities/STUS | Is part of AB. |
| (F) S | SYOC Synthesis of Costs | F private sector/SYOC | Is part of AB. Synthesis of costs and benefits. |
| (F) S | TI Title | F health/TI | The field TI is equivalent to the field RTI. Is part of SO and contains PLA.The Title of the original article are showed additional in TI and is part of the free text search. |
| (F) S | TOEE Type of Economic Evaluation | F cost effectiveness analysis/TOEE | Is part of AB. |
| (F) S | TOI Type of Intervention |
F diagnosis/TOI | Is part of AB. |
| S | URL URL | URL: http://www.ama-assn.org/surgery | |
| (F) S | VEC Validity of Estimate of Costs | F underestimated /VEC | Is part of AB. |
| (F) S | VEMB Validity of Estimate of Measure of benefit | F clinical outcomes/VEMB | Is part of AB. |
| (F) S | VEME Validity of Estimate of Measure of Effectiveness | F differences/VEME | Is part of AB. |
Output of Search Results
By means of the commands SHOW (S) / MAIL / SDI.
Corresponding to the copyright rules use the parameter USE=DLOAD if necessary.
You may ask for all data fields, single data fields, or sets of data fields. If the output fields are not specified explicitly, the standard field set (F=STD) is used in all output commands.
Output field sets:
| Command | Field Set | Associated Datafields |
|---|---|---|
| F=STD | Standard | same as F=ALL |
| F=ALL | all fields | ND, CA, AU (=RA), TI (=RTI, incl. PLA), SO (incl. TI), RSO (incl. RVOL, RPG, PY), PU, LA, PLA, CY, ISSN, CS, DT, CT, STA, CNOTE, AB (see F=AB), URL |
| F=BIB | bibliographic fields | ND, CA, AU (=RA), TI (=RTI, incl. PLA) , SO (incl. TI), RSO (incl. RVOL, RPG, PY), PU, LA, PLA, CY, ISSN, CS, DT |
| F=AB | abstract | HT, DIS, TOI, HYSQ, ECST, STUP, SETT, DDR, SRCE, SRCF, LBEC, STUS, STUD, AEFF, EFFR, CLC, MOD, OUT, STUI, SRCS, CRI, MJUD, NRPS, MCOM, INVS, RES, MEFF, ESEF, MOB, CDIR, CIDIR, CUR, CSTAT, SENS, ESEC, CRES, SYOC, CRD, IMPS, OTHER, AC |
| F=REF | references | RSO (incl. JT, RVOL, RPG, PY) |
Sample Search(es)
Subject: Studies about HPV vaccination
1. Search via DIMDI SmartSearch
2. Search via DIMDI ClassicSearch
Profile table:
| Parameter | Counter | Number of Hits | Query |
|---|---|---|---|
| C= | 1 | 28991 | NHSEED |
| S= | 2 | 72 | CT D PAPILLOMAVIRUS VACCINES |
| 3 | 8238 | DT=ABSTRACT | |
| 4 | 22 | 2 AND 3 |
Sample Record(s)
DIMDI: NHS Economic Evaluation Database (NHSEED) © 2011 University of York. Published by John Wiley & Sons, Ltd.
| ND: | NHSEED-22009100806 |
| CA: | Centre for Reviews and Dissemination |
| AU: | Coupe VM; van Ginkel J; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J |
| TI: | HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness (Structured abstract) |
| SO: | NHS Economic Evaluation Database (NHSEED). Critically appraised economic evaluations. Abstract of: HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness |
| RSO: | International Journal of Cancer; VOL: 124 (4); p. 970-978 /2009/ |
| PU: | John Wiley & Sons, Ltd, Chichester, UK |
| LA: | English |
| ISSN: | 1465-1858 |
| DT: | Abstract |
| CT: | Adult; Child; Female; Humans; Middle Aged; Adolescent; Computer Simulation; Cost-Benefit Analysis; Early Detection of Cancer; Human papillomavirus 16; Human papillomavirus 16/immunology; Human papillomavirus 18; Human papillomavirus 18/immunology; Papillomavirus Infections; Papillomavirus Infections/economics; Papillomavirus Infections/prevention & control; Papillomavirus Vaccines; Papillomavirus Vaccines/economics; Quality-Adjusted Life Years; Uterine Cervical Neoplasms; Uterine Cervical Neoplasms/prevention & control; Uterine Cervical Neoplasms/virology; Vaccination; Vaccination/economics |
| STA: | This record was compiled by CRD commissioned reviewers according to a set of guidelines developed in collaboration with a group of leading health economists. |
| URL: | http://www3.interscience.wiley.com/journal/121410208/abstract |
| STUO: | This study examined the cost-effectiveness of human papillomavirus (HPV) vaccination for girls aged 12 years, in addition to conventional cervical cancer screening. |
| INT: | The vaccination protected against HPV types 16 and 18 for girls aged 12 years, while the cervical cancer screening consisted of cytological screening once every five years for women aged between 30 and 60 years. Four strategies were considered: no intervention; screening only; vaccination only; and screening plus vaccination. |
| SRCF: | Supported by a grant from GlaxoSmithKline. |
| LOSE: | Netherlands/primary care. |
| TOEE: | Cost-utility analysis |
| METH: | Analytical approach: A computer simulation of 14 Markov chains
(one for each HPV type), with a lifetime horizon, was developed to
estimate the costs and benefits of the four strategies. The authors
did not explicitly state the perspective adopted. Effectiveness data: The clinical evidence came from selected sources of data. Most of the epidemiological data and transition probabilities were from local studies, including Dutch cohort studies and a population-based screening trial of 44,102 women. Few details of these sources were reported. The data on the incidence of disease were the key estimates. The data on vaccine efficacy and screening accuracy were from published studies, the details of which were not given. ... |
| RES: | The expected costs were EUR 139.73 with screening only and EUR
464.19 with vaccination (95% efficacy; 85% coverage; and lifelong
protection) and screening. The QALYs were 42.6908 with screening
only and 42.7075 with vaccination and screening. Vaccination alone
was less effective than the combined strategy. The incremental cost per QALY gained with vaccination and screening over screening alone was EUR 19,429, which was very close to the Dutch cost-effectiveness threshold of EUR 20,000 per QALY. ... |
| CRD: | Interventions: The authors justified their selection of the
comparators. The screening programme reflected the current Dutch
guidelines, while the vaccination strategy was the proposed
intervention. The details of the current pattern of care were
reported. Effectiveness/benefits: Limited information about the clinical analysis was reported. The authors did not state how they identified the relevant sources of evidence, which may have been known to the authors. Dutch sources and large cohort studies were used for most of the epidemiological data, which was appropriate, but the methods and other characteristics of these data sources were not reported. Similarly, no clear information on the sources of the utility estimates was provided. QALYs were valid benefit measure given their comparability with the benefits of other interventions and the impact of the disease on both quality of life and survival. ... |
| CSUM: | This study examined the cost-effectiveness of human papillomavirus (HPV) vaccination for girls aged 12 years, in addition to conventional cervical cancer screening. The authors concluded that HPV16/18 vaccination in young women, in addition to screening, was a cost-effective strategy. The clinical and economic sources were not fully described, but the study used appropriate and sophisticated methodology, which enhances the validity of the authors} conclusions. |
| AC: | The authors concluded that HPV16/18 vaccination in young women, in addition to cervical cancer screening, was a cost-effective strategy. |
full
text
Output format: SHOW F=ALL
The sample record is reduced in its length.
Contact
Producer
- Centre for Reviews and Dissemination (CRD)
University of York
York YO10 5DD
Great Britain
Phone: +44 1904 321040
Fax: +44 1904 321041
Contact Person
- Database Search:
DIMDI
Phone: +49 221 4724-315
E-mail: Helpdesk Databases - Service, Contract, Prices:
DIMDI
Phone: +49 221 4724-270
E-mail: Technical Helpdesk
Appendix
Appendix
Alphabetical List of Qualifiers
| Year of Introduction | Qualifier |
|---|---|
| 66 | AB: abnormalities |
| 66 | AD: administration & dosage |
| 66 | AE: adverse effects |
| 95 | AG: agonists |
| 75 | AA: analogs & derivatives |
| 67 | AN: analysis |
| 66 | AH: anatomy & histology |
| 68 | AI: antagonists & inhibit. |
| 66 | BI: biosynthesis |
| 67 | BL: blood |
| 66 | BS: blood supply |
| 67 | CF: cerebrospinal fluid |
| 68 | CS: chemical synthesis |
| 67 | CI: chemically induced |
| 91 | CH: chemistry |
| 66 | CL: classification |
| 66 | CO: complications |
| 66 | CN: congenital |
| 91 | CT: contraindications |
| 67 | CY: cytology |
| 75 | DF: deficiency |
| 66 | DI: diagnosis |
| 67 | DU: diagnostic use |
| 75 | DH: diet therapy |
| 66 | DE: drug effects |
| 66 | DT: drug therapy |
| 78 | EC: economics |
| 67 | ED: education |
| 66 | EM: embryology |
| 66 | EN: enzymology |
| 66 | EP: epidemiology |
| 03 | ES: ethics |
| 75 | EH: ethnology |
| 66 | ET: etiology |
| 78 | GE: genetics |
| 66 | GD: growth & development |
| 66 | HI: history |
| 66 | IM: immunology |
| 66 | IN: injuries |
| 66 | IR: innervation |
| 66 | IS: instrumentation |
| 66 | IP: isolation & purific. |
| 78 | LJ: legisl. & jurispr. |
| 68 | MA: manpower |
| 66 | ME: metabolism |
| 75 | MT: methods |
| 67 | MI: microbiology |
| 67 | MO: mortality |
| 66 | NU: nursing |
| 78 | OG: organizat. & administ. |
| 75 | PS: parasitology |
| 66 | PY: pathogenicity |
| 66 | PA: pathology |
| 88 | PK: pharmacokinetics |
| 67 | PD: pharmacology |
| 66 | PH: physiology |
| 66 | PP: physiopathology |
| 66 | PO: poisoning |
| 66 | PC: prevention & control |
| 78 | PX: psychology |
| 66 | RE: radiation effects |
| 67 | RA: radiography |
| 78 | RI: radionuclide imaging |
| 66 | RT: radiotherapy |
| 67 | RH: rehabilitation |
| 80 | SC: secondary |
| 68 | SE: secretion |
| 68 | ST: standards |
| 89 | SN: statistics & numer.data |
| 68 | SD: supply & distribution |
| 66 | SU: surgery |
| 66 | TU: therapeutic use |
| 66 | TH: therapy |
| 66 | TO: toxicity |
| 75 | TM: transmission |
| 66 | TR: transplantation |
| 78 | TD: trends |
| 91 | US: ultrasonography |
| 75 | UL: ultrastructure |
| 67 | UR: urine |
| 68 | UT: utilization |
| 66 | VE: veterinary |
| 95 | VI: virology |
- Copyright: DIMDI -
All intellectual property rights of this document, also concerning reproduction and distribution, are reserved by DIMDI.